Annovis Bio, Inc. (ANVS)
NYSE: ANVS · Real-Time Price · USD
2.090
+0.080 (3.98%)
Mar 31, 2026, 10:07 AM EDT - Market open

Annovis Bio Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-28.85-24.59-56.2-25.33-14.49
Stock-Based Compensation
1.83.844.639.154.7
Other Adjustments
-0.14-1.8211.84--
Changes in Accounts Payable
0.281.01-2.673.270.35
Changes in Accrued Expenses
-0.53-1.41-0.752.920.58
Changes in Other Operating Activities
1.821.083.19-7.33-0.27
Operating Cash Flow
-25.62-21.89-39.97-17.31-9.13
Issuance of Common Stock
34.626.6917.34046.74
Net Common Stock Issued (Repurchased)
34.626.6917.34046.74
Financing Cash Flow
34.626.6917.34046.74
Net Cash Flow
8.984.8-22.62-17.3137.61
Free Cash Flow
-25.62-21.89-39.97-17.31-9.13
Free Cash Flow Per Share
-1.25-1.79-4.43-2.12-1.20
Levered Free Cash Flow
-27.28-23.91-56.43-26.47-13.83
Unlevered Free Cash Flow
-28.12-26.01-45.26-26.65-13.88
Updated Mar 13, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q